Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck launches Lexapro in Japan

Danish pharmaceutical company Lundbeck is to launch its antidepressant Lexapro (escitalopram oxalate) in Japan

Danish pharmaceutical company Lundbeck is to launch its antidepressant Lexapro (escitalopram oxalate) in Japan.

The drug will be co-marketed in the country by Lundbeck and Japanese pharmaceutical firm Mochida, following an agreement made in January 2010.

Financial terms of the deal have not been disclosed, but Lundbeck is due to receive regulatory milestone payments and royalties on sales.

Lexapro was approved following clinical phase III studies in Japan that confirmed its efficacy and tolerability.

The companies say they estimate sales of Lexapro amounting to 3bn Yen for the first year following the launch and 33.8bn Yen during 2018 when revenue will be at its peak.

22nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics